This pilot and feasibility project culminated from two concurrent discoveries in a collaboration between the PI and the co-Pi that reveal novel mechanisms for up-regulating proteins that compensate for dystrophindeficiency. First, we identified a FDA-approved compound, compound 6, that increases glycosylation of glycoproteins at the muscle cell surface, which in turn 1) enhances muscle cell interaction with components of the extracellular matrix and 2) increases abundance of dystrophin- and utrophin-glycoprotein complexes. Serendipitously, we found that introduction of sarcospan, a small transmembrane component of the dystrophin-glycoprotein complex, has identical effects. Overexpression of sarcospan ameliorates dystrophy by stabilizing the utrophin-glycoprotein complex throughout the sarcolemma and increasing surface glycosylation. We propose to investigate mechanisms by which altered cell surface glycosylation enhances muscle cell function with the goal of developing these discoveries into therapies for DMD. We will identify the types of glycans that are modified by compound 6 treatment and sarcospan overexpression, as well as the glycoproteins that bear these modified glycans. We will investigate the roles of the modified glycoproteins in the enhanced binding of laminin that we have observed when muscle cells are treated with compound 6. We will interrogate the interaction of laminin with dystrophin- and utrophin-glycoprotein complexes on the surface of cells treated with compound 6, to understand how this drug alters subcellular localization and/or stability of these complexes. We will test the efficacy of compound 6 in the mdx mouse model as well as one other model of congenital muscular dystrophy. This application addresses the primary defect in DMD and other congenital muscular dystrophies, as the results of this work may be broadly applicable to congenital dystrophies resulting from defects in glycosylation, such as Walker-Warburg Syndrome, muscle-eye-brain disease, Fukuyama congenital muscular dystrophy, and congenital muscular dystrophies type-1 B, -1C and - 1D. This pilot and feasibility project will rely on expertise and services provided by Core B (High-throughput Screening), Core C (Muscle Phenotyping and Imaging), and Core D (Bioinformatics and Genomics).

Public Health Relevance

The current proposal directly fulfills the mission to identify and test novel treatments for Duchenne muscular dystrophy and may be broadly applicable to congenital dystrophies resulting from defects in glycosylation. The current proposal culminated from two concurrent discoveries in a collaboration between the PI and the co-Pi that reveal novel mechanisms for up-regulating proteins that compensate for dystrophin-deficiency.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
1P30AR057230-01
Application #
7680821
Study Section
Special Emphasis Panel (ZAR1-CHW-G (M1))
Project Start
2009-04-01
Project End
2011-03-31
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
1
Fiscal Year
2009
Total Cost
$118,604
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Hicks, Michael R; Hiserodt, Julia; Paras, Katrina et al. (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20:46-57
Armstrong, Tess; Dregely, Isabel; Stemmer, Alto et al. (2018) Free-breathing liver fat quantification using a multiecho 3D stack-of-radial technique. Magn Reson Med 79:370-382
Wang, Richard T; Barthelemy, Florian; Martin, Ann S et al. (2018) DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype. Hum Mutat 39:1193-1202
Wang, Derek W; Mokhonova, Ekaterina I; Kendall, Genevieve C et al. (2018) Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse. Mol Ther Nucleic Acids 11:180-191
Kramerova, Irina; Torres, Jorge A; Eskin, Ascia et al. (2018) Calpain 3 and CaMKII? signaling are required to induce HSP70 necessary for adaptive muscle growth after atrophy. Hum Mol Genet 27:1642-1653
Aliotta, Eric; Moulin, Kévin; Magrath, Patrick et al. (2018) Quantifying precision in cardiac diffusion tensor imaging with second-order motion-compensated convex optimized diffusion encoding. Magn Reson Med 80:1074-1087
Gibbs, Elizabeth M; Crosbie-Watson, Rachelle H (2017) A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy. J Vis Exp :
Peter, Angela K; Miller, Gaynor; Capote, Joana et al. (2017) Nanospan, an alternatively spliced isoform of sarcospan, localizes to the sarcoplasmic reticulum in skeletal muscle and is absent in limb girdle muscular dystrophy 2F. Skelet Muscle 7:11
Young, Courtney S; Mokhonova, Ekaterina; Quinonez, Marbella et al. (2017) Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy. J Neuromuscul Dis 4:139-145
Rai, Muhammad Farooq; Duan, Xin; Quirk, James D et al. (2017) Post-Traumatic Osteoarthritis in Mice Following Mechanical Injury to the Synovial Joint. Sci Rep 7:45223

Showing the most recent 10 out of 71 publications